Jorvi Hospital
- Address
- lock Available on a paid plan
Psychiatry and Psychology
At Jorvi Hospital, clinical research in mental disorders focuses on schizophrenia and related cognitive impairment. The main aim is to gather additional safety information and better understand how ongoing treatment strategies may support people living with these conditions.
- Long-term safety and tolerability research in schizophrenia
- Support for patients with cognitive symptoms linked to mental illness
- Evaluation of treatment effects in people who previously participated in a clinical study
This work helps expand knowledge of psychiatric care and supports the development of safer, more effective options for patients with schizophrenia.
Analytical, Diagnostic and Therapeutic Techniques and Equipment
Surgical research at this hospital includes studies on venous thromboembolism in patients undergoing surgery. The focus is on improving prevention strategies and weighing the benefits and risks of thromboprophylaxis for people whose clotting and bleeding risks are not clearly high.
- Prevention of blood clots after urologic, gynecologic, and abdominal surgery
- Comparison of standard care alone versus added anticoagulant protection
- Better understanding of safety and effectiveness in surgical patients
These trials support safer surgical care by refining approaches to blood clot prevention and postoperative risk management.
Neoplasms
In the area of cancer research, the site is studying colorectal cancer, particularly tumors with specific PIK3CA-related alterations. The research aims to see whether an additional treatment approach can help delay recurrence after initial cancer care.
- Recurrence prevention in stage II-III colon and rectal cancer
- Research on tumors with somatic changes in the PI3K signaling pathway
- Evaluation of a treatment strategy to improve long-term cancer control
This line of investigation at Jorvi Hospital is designed to improve outcomes for patients with gastrointestinal cancer by testing whether treatment can reduce the chance of the disease returning.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 3 by active trials.
- 1HUS-yhtymae1active
lock +2 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
No repeated partnerships found.
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 107 other sites in Finland
Therapeutic Area Benchmark — Finland
Select a therapeutic area to compare against other sites in Finland.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Finland
Market Share
Country: Finland
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Jorvi Hospital
lock Showing 1 of 4 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| Efficacy and Safety Evaluation of Subcutaneous Selatogrel in Preventing Recurrent Acute Myocardial Infarction in Post-AMI Patients | Viatris Innovation GmbH | Phase III | Recruiting | Jan 2022 | — |
IMP list
lock Showing 1 of 4 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Acetylsalicylic Acid | 1 | Unknown | — | — |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.
